Pacific Biosciences Of California (PACB) Raw Materials (2011 - 2026)

Pacific Biosciences Of California's Raw Materials history runs 16 years deep, the most recent figure standing at $34.7 million for Q1 2026.

• On a quarterly basis, Raw Materials fell 21.9% year-over-year to $34.7 million in Q1 2026; TTM through Mar 2026 was $34.7 million, a 21.9% decrease from a year earlier, with the FY2025 full-year figure at $38.6 million, down 14.65% from the prior year.
• Raw Materials eased to $34.7 million in Q1 2026 per PACB's latest filing, from $38.6 million in the prior quarter.
• Across five years, Raw Materials topped out at $46.0 million in Q2 2025 and bottomed at $11.5 million in Q1 2022.
• The 5-year median for Raw Materials is $29.9 million (2024), against an average of $30.2 million.
• Across the five-year window, Raw Materials jumped 202.0% in 2022 and declined 21.9% in 2026, its largest moves.
• Year by year, Raw Materials stood at $24.1 million in 2022, then surged by 34.36% to $32.4 million in 2023, then soared by 39.58% to $45.3 million in 2024, then fell by 14.65% to $38.6 million in 2025, then slipped by 10.1% to $34.7 million in 2026.
• Per Business Quant, the three latest PACB Raw Materials figures stand at $34.7 million (Q1 2026), $38.6 million (Q4 2025), and $41.8 million (Q3 2025).